Aureus is involved in gathering high quality quantitative biological activity data of major therapeutic drugs, which enables researchers to identify the promising compounds, repurpose existing compounds as well as identify targets with which the new compounds might interact.
Under the acquisition, Elsevier will combine Aureus’ content assets and its already available content to launch new solutions for pharmaceutical and biotech users.
The first combined solution, a new medicinal chemistry solution, will be launched early in 2013.
Aureus Sciences CEO Jason Theodosiou said, "The integration of Aureus into Elsevier, and the consolidation of best in class content, will complement Elsevier’s leadership in biomedical disciplines and strengthen our ability to offer new innovative databases to researchers in medicinal chemistry and pharmacology."